(Q43260540)

English

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

scientific article published on 15 October 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Jaroslaw Cwikla

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Krzysztof Jeziorski

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

A Sankowski

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

N Seklecka

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J R Buscombe

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

A Nasierowska-Guttmejer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

R Mikolajczak

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

D Pawlak

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

K Stepien

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

J Walecki

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

15 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

787-794

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19833821%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP372

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43260540&oldid=1651513204"